Previous 10 | Next 10 |
Precigen (NASDAQ: PGEN ) +5% on disclosing that its Chairman Randal Kirk bought an aggregate of 1.2M shares for $5.35M. More news on: Precigen, Inc., Healthcare stocks news, Read more ...
Ligand reports planned acquisition of Pfenex Ligand Pharmaceuticals Inc. ( LGND ) announced that it has inked a definitive agreement with Pfenex Inc. ( PFNX ) for acquiring the latter. The companies expect the transaction to be closed in the fourth quarter of 2020, subject to required re...
The following slide deck was published by Precigen, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Gainers: Biofrontera (NASDAQ: BFRA ) +75% . More news on: Biofrontera AG, Pfenex Inc., Oxbridge Re Holdings Limited, Stocks on the move, , Read more ...
Image source: The Motley Fool. Precigen, Inc. (NASDAQ: PGEN) Q2 2020 Earnings Call Aug 10, 2020 , 4:30 p.m. ET Operator Continue reading
Precigen, Inc. (PGEN) Q2 2020 Earnings Conference Call August 10, 2020, 16:30 ET Company Participants Steven Harasym - Head, IR Helen Sabzevari - President, CEO & Director Tom Samuelson - Head, Financial Strategy Conference Call Participants Douglas Buchanan - JMP Secur...
Precigen (NASDAQ: PGEN ) : Q2 GAAP EPS of -$0.26 misses by $0.12 . More news on: Precigen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
GERMANTOWN, Md. , Aug. 10, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half financial results fo...
Precigen's ( PGEN +0.8% ) subsidiary Precigen ActoBio, has announced that its Phase 1b monotherapy portion of the ongoing Phase 1b/2a AG019 trial, has met the primary endpoint for the treatment of early-onset type 1 diabetes. More news on: Precigen, Inc., Healthcare stocks news,...
GERMANTOWN, Md. , Aug. 10, 2020 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced it has met the primary en...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...